Skip to content

Abstract 15137: Novel Obesity Frameworks and Risk of Incident Cardiovascular-Kidney-Metabolic Outcomes and Mortality: Findings from the All of Us and UK Biobank

Nov 2026 · Circulation · 0 citations

Abstract

Background: The cardiovascular-kidney-metabolic (CKM) construct recognizes excess and dysfunctional adiposity as a key driver of cardiovascular risk. Novel obesity frameworks, the 2024 European Association for the Study of Obesity (EASO) and the 2025 Lancet Diabetes and Endocrinology Commission definitions, extend beyond the traditional WHO body mass index (BMI) based diagnosis, to better identify excess adiposity, but their diagnostic agreement and prognostic implications remain unclear. Objectives: To quantify diagnostic discordance between the EASO and Lancet frameworks and assess their associations with incident CKM outcomes and mortality. Methods: We conducted a prospective cohort analysis using the All of Us Research Program (AoU; n=313,019) and UK Biobank (UKBB; n=502,233). We included adults with complete and biologically plausible anthropometric measurements and linked electronic health record (EHR) data for outcome ascertainment. Participants were classified into four diagnostic groups: no obesity by either framework, EASO-only obesity, Lancet-only obesity, and obesity by both frameworks. Agreement between frameworks was assessed using Gwet's AC1. Incident atherosclerotic cardiovascular disease (ASCVD composite), myocardial infarction (MI), stroke, heart failure (HF), chronic kidney disease (CKD), and all-cause mortality were evaluated using Cox proportional hazards models. Results: The Lancet framework identified a higher prevalence of obesity than EASO in both cohorts (AoU: 68.7% vs. 56.2%; UKBB: 69.0% vs. 41.1%). Agreement between frameworks was only moderate (Gwet’s AC1=0.56), with diagnostic discordance observed in 17.5% (AoU) and 29.1% (UKBB), driven predominantly by Lancet-only obesity classifications. Baseline obesity-related complications were more common in AoU than UKBB (50.5% vs. 10.6%) and were most prevalent among participants classified as obese by both frameworks and among EASO-only obesity groups in both cohorts. In adjusted analyses, the obesity by both frameworks group exhibited the highest risk across all outcomes in UKBB, and all outcomes except all-cause mortality in the AoU cohort. EASO-only obesity groups showed elevated risk in AoU (except for all-cause mortality) but no association in UKBB, whereas Lancet-only obesity groups did not show any increased CKM associations in AoU or UKBB. Conclusion: Diagnostic discordance between the Lancet and EASO frameworks is substantial. The EASO diagnostic construct preferentially identifies individuals with a higher cardiometabolic risk profile, whereas the Lancet framework captures a broader spectrum of obesity, including earlier preclinical disease stages. These findings may have important implications for obesity risk stratification and prognostication.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.